Trial Profile
A multicentre, double-blind, placebo-controlled evaluation of intranasal sumatriptan delivered with the OptiNose powder device in the treatment of acute migraine.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jul 2011
Price :
$35
*
At a glance
- Drugs Sumatriptan (Primary)
- Indications Migraine with aura; Migraine without aura
- Focus Therapeutic Use
- 27 Jul 2011 New trial record